Coronary thrombolysis by intravenous infusion of recombinant single chain urokinase-type plasminogen activator or recombinant urokinase in baboons: effect on regional blood flow, infarct size and hemostasis
- PMID: 3086416
- DOI: 10.1016/s0735-1097(86)80101-2
Coronary thrombolysis by intravenous infusion of recombinant single chain urokinase-type plasminogen activator or recombinant urokinase in baboons: effect on regional blood flow, infarct size and hemostasis
Abstract
An occlusive thrombus was produced by thrombin-induced coagulation in the left anterior descending coronary artery of 18 open chest baboons. In six control animals, occlusive thrombosis persisting for 4 hours resulted in a large transmural infarct (66 +/- 4% of the perfusion area, mean +/- SEM). In six animals, single chain urokinase-type plasminogen activator, obtained by recombinant deoxyribonucleic acid (DNA) technology, was infused intravenously at a rate of 20 micrograms/kg per min for 60 minutes after approximately 45 minutes of coronary thrombosis. Persistent reperfusion occurred within 21 +/- 4 minutes (mean +/- SD). The mean duration of occlusion before reperfusion was 72 +/- 6 minutes. Recanalization resulted in a reduction of infarct size (42 +/- 4%, p less than 0.01 versus control animals). Myocardial blood flow in the perfusion area of the left anterior descending coronary artery was 107% of normal 2.5 hours after recanalization. The infusion of recombinant single chain urokinase-type plasminogen activator was not associated with systemic activation of the fibrinolytic system, fibrinogen breakdown or evident bleeding. In six baboons recombinant low molecular weight urokinase (molecular weight 33,000) was infused intravenously at a rate of 20 micrograms/kg per min for 60 minutes after approximately 45 minutes of coronary thrombosis. Persistent reperfusion occurred within 14 +/- 5 minutes (p less than 0.05 versus recombinant single chain urokinase-type plasminogen activator). The mean duration of occlusion was 69 +/- 14 minutes.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
Coronary thrombolysis and infarct size reduction after intravenous infusion of recombinant tissue-type plasminogen activator in nonhuman primates.J Clin Invest. 1985 Jan;75(1):84-90. doi: 10.1172/JCI111701. J Clin Invest. 1985. PMID: 4038406 Free PMC article.
-
Recombinant single-chain urokinase-type plasminogen activator during acute myocardial infarction.Am J Cardiol. 1988 May 1;61(13):966-70. doi: 10.1016/0002-9149(88)90107-5. Am J Cardiol. 1988. PMID: 2452563 Review.
-
Synergistic combinations of recombinant human tissue-type plasminogen activator and human single-chain urokinase-type plasminogen activator. Effect on thrombolysis and reocclusion in a canine coronary artery thrombosis model with high-grade stenosis.Circulation. 1989 Feb;79(2):393-9. doi: 10.1161/01.cir.79.2.393. Circulation. 1989. PMID: 2492455
-
Coronary arterial thrombolysis with low-dose synergistic combinations of recombinant tissue-type plasminogen activator (rt-PA) and recombinant single-chain urokinase-type plasminogen activator (rscu-PA) for acute myocardial infarction.Am J Cardiol. 1987 Sep 1;60(7):431-4. doi: 10.1016/0002-9149(87)90280-3. Am J Cardiol. 1987. PMID: 3115077
-
Coronary thrombolysis for evolving myocardial infarction.Drugs. 1984 Nov;28(5):465-83. doi: 10.2165/00003495-198428050-00004. Drugs. 1984. PMID: 6391890 Review.
Cited by
-
Saruplase in Myocardial Infarction.J Thromb Thrombolysis. 1995;2(3):195-204. doi: 10.1007/BF01062710. J Thromb Thrombolysis. 1995. PMID: 10608024
-
Comparison of the Pharmacokinetics and Effects on the Hemostatic System of Saruplase and Urokinase in Patients with Acute Myocardial Infarction.J Thromb Thrombolysis. 1996;3(4):385-390. doi: 10.1007/BF00133082. J Thromb Thrombolysis. 1996. PMID: 10602568
-
A Double-Blind Multicenter Comparison of the Efficacy and Safety of Saruplase and Urokinase in the Treatment of Acute Myocardial Infarction: Report of the SUTAMI Study Group.J Thromb Thrombolysis. 1995;2(2):117-124. doi: 10.1007/BF01064379. J Thromb Thrombolysis. 1995. PMID: 10608014
-
Pharmacokinetics and hemostatic effects of saruplase in patients with acute myocardial infarction: comparison of infusion, single-bolus, and split-bolus administration.J Thromb Thrombolysis. 1999 Oct;8(3):213-21. doi: 10.1023/a:1008914321384. J Thromb Thrombolysis. 1999. PMID: 10500311 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical